Prevalence and Associations of Cognitive Impairment in Adult Patients with Moyamoya Disease: A Systematic Review and Meta-Analysis
Related Experiment Video
Updated: Jul 8, 2025
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Keith Z X Toh1, Ming Yi Koh1, Enver D W Loh1
1Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
Background:
Cognitive impairment, and in the long term Alzheimer's disease, vascular, or mixed dementia, are potential complications of moyamoya disease (MMD), of which the prevalence and associations are not well established.
Objective:
We performed a systematic review and meta-analysis to investigate the prevalence of cognitive impairment in adult patients with MMD as well as its clinical and demographic correlates.
Methods:
We performed a systematic search of four electronic databases: PubMed (MEDLINE), EMBASE, Scopus, and Cochrane Library, profiling studies from inception until 7 May 2023. Clinical data consisting of population characteristics, comorbidities, cognitive assessment tools used, and prevalence of cognitive impairment was extracted.
Results:
Seventeen studies were included in the meta-analysis, with a total study population of 1,190 patients. All studies assessed cognition, and the overall prevalence of cognitive impairment in MMD patients was 54.59%. A subgroup analysis identified that the prevalence of executive dysfunction in MMD patients was 31.55%. We performed a meta-regression analysis which identified that cognitive impairment was not associated with age, education level, or a history of ischemic or hemorrhagic stroke.
Conclusions:
A substantial proportion of MMD patients have cognitive impairment, and cognitive impairment was found to have no association with a history of stroke. Further research is necessary to investigate the longitudinal relationship of MMD and cognitive impairment, and the impact of bypass surgery on cognitive impairment.
Insights
Over half of patients with moyamoya disease (MMD) experience cognitive impairment. This study found no link between cognitive issues and stroke history in MMD patients, highlighting a need for further research.
Area of Science:
- Neurology
- Neuroscience
- Medical Research
Background:
- Moyamoya disease (MMD) can lead to cognitive impairment, including dementia, but prevalence and associations are unclear.
- Understanding cognitive decline in MMD is crucial for patient management and prognosis.
Approach:
- A systematic review and meta-analysis was conducted, searching major databases up to May 2023.
- Seventeen studies comprising 1,190 adult MMD patients were analyzed for cognitive impairment prevalence and correlates.
Key Points:
- The overall prevalence of cognitive impairment in MMD patients was 54.59%.
- Executive dysfunction was present in 31.55% of MMD patients.
- Cognitive impairment was not associated with age, education, or prior stroke history.
Conclusions:
- A significant portion of MMD patients suffer from cognitive impairment.
- The absence of a link between cognitive impairment and stroke history warrants further investigation.
- Longitudinal studies are needed to explore MMD's impact on cognition and the effect of surgical interventions.
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...